Abstract: Percutaneous therapies for congenital heart disease have been evolving rapidly despite limited investment from industry. The Melody transcatheter pulmonary valve (Medtronic, Inc, Minneapolis, MN USA) replacement therapy represents an important advancement in this arena. It has been approved in the United States for use in the pulmonary position, on a Humanitarian Device Exemption status. Off-label use of the Melody transcatheter pulmonary valve has extended to the mitral, pulmonary, and aortic valves, especially in previously implanted valves with prosthetic valve degeneration. The single-ventricle patient poses additional challenges. However, there exists one report in the English literature of a patient undergoing Melody transcatheter neoaortic valve replacement after the patient developed severe neoaortic regurgitation after Fontan palliation. Here, we describe a patient with hypoplastic left heart syndrome, palliated with a Norwood modified Blalock-Taussig shunt, with a progressively regurgitant quadricusp neoaortic valve who underwent bioprosthetic valve replacement. There was early prosthetic valve degeneration after a year of bioprosthesis implantation. As he was declined for transplantation, he underwent successful perventricular Melody valve-in-valve replacement.
B
efore introduction of the Melody valve (Medtronic, Inc, Minneapolis, MN USA) in 2000, patients received either prosthetic valves or allograft conduits for management of severe pulmonary insufficiency. The Melody valve is a valved bovine jugular vein mounted within a platinum-iridium stent. A modified Melody valve can be designed to have an adjustable diameter that can be expanded with somatic growth in the catheterization laboratory. Developed for implantation into the right ventricle outflow tract, the valve has demonstrated acute valvular competence within a size range of 10 to 22 mm. 1 This device is currently approved in the United States for implantation in the pulmonary position on a Humanitarian Device Exemption status. The Melody valve allows for decreased sternotomies and cardiopulmonary bypass runs as we can now lengthen the longevity of right ventricle to pulmonary artery conduits or provide pulmonary competence in other patients. 2 Because of limited investment from industry and support from regulatory bodies, there has been a lack of device development. This has resulted in off-label use of the Melody valve in the tricuspid, mitral, and even aortic positions, especially in patients with previous valve replacements in these positions. 3 Short-term performance of the valve in a high-pressure environment, both in the systemic and pulmonary circulations, has done well, with 100% freedom from regurgitation at 1 year. 4 Patients with single-ventricle physiology pose additional challenges, but transcatheter replacement of the native neoaortic valve has been described. 3, 5 
CASE REPORT
A 3-kg male infant with a diagnosis of hypoplastic left heart syndrome (mitral stenosis, aortic stenosis) and a mildly regurgitant quadricuspid pulmonary valve underwent a Norwood procedure with a modified Blalock-Taussig shunt (3.5 mm) in April 2013. After discharge, his course was complicated by multiple admissions for poor ventricular function, neoaortic regurgitation, and failure to thrive. Cardiac catheterization with stenting of the modified Blalock-Taussig shunt, ballooning of stenotic left pulmonary veins, and dilation of coarctation was performed. At 5 months of age (4.9 kg), a 19-mm Mitroflow bioprosthetic valve (Sorin Group, London, UK) was implanted in the neoaortic position using the Konno technique to enlarge the neoaortic root. At 1 year of age (7.3 kg), the child underwent repair of the tricuspid valve for moderate insufficiency, mBT shunt up sizing to 5 mm, and sutureless repair of left pulmonary vein stenosis. Secondary to progressive decline in ventricular function and severe prosthetic valve stenosis, he was evaluated but declined for cardiac transplantation by multiple centers.
At age of 2 years (9.2 kg), the patient was admitted to the hospital with cardiac and respiratory decompensation. Blood cultures were found to be positive for Chryseobacterium indologenes and Candida parapsilosis, and there was concern for bioprosthetic endocarditis. However, echocardiography did not reveal any valvular vegetation. Infectious disease help was sought, and the presumed endocarditis was treated with levofloxacin and cefepime. Negative blood cultures were obtained; however, the child remained ventilator dependent secondary to severe heart failure and a failing bioprosthetic valve causing severe valvar stenosis and progressive tricuspid valve insufficiency (Fig. 1) . Because the child was declined for transplantation at multiple centers, we chose to entertain a less invasive approach to the management of severe prosthetic valve stenosis rather than a complex reoperation and valve replacement. Consent for the off-label use of a humanitarian device was obtained.
This procedure was performed with the cardiopulmonary bypass machine on standby. A redosternotomy was performed. The neoaorta and a portion of the atrium were exposed to allow for easy cannulation, if needed. An additional left anterolateral thoracotomy was made lateral to the inferior end of the sternotomy to allow access to the anterior surface and apex of the right ventricle. Using a 21-gauge micropuncture needle, the right ventricle was punctured at the apex within a pursestring suture. A micropuncture wire was advanced within the needle and into the ascending aorta. The needle was removed, and a 6F sheath was advanced over the needle, through the right ventricular wall and the tip positioned in the ascending aorta. The micropuncture wire was exchanged for a 4F Glide catheter (Terumo International Systems, Sumeset, NJ USA), Wholey wire (Covidien, Minneapolis, MN USA) was advanced within the sheath, and the Glide catheter was positioned in the distal right subclavian. The Wholey wire was removed and exchanged for an Amplatzer super stiff 0.035″ wire (AGA Medical Corporation, North Plymouth, MN USA). The super stiff wire was parked in the distal right subclavian artery, and the Glide catheter and sheath were removed over the wire.
A Melody valve was prepared in the usual fashion and mounted on a 22-mm Ensemble delivery system (Medtronic, Inc, Minneapolis, MN USA). The Ensemble system was advanced over the wire, and the valve centered within the Mitroflow valve. After positioning was confirmed by both fluoroscopy and angiography, the valve was delivered by inflating the balloon to 6 atm. The Ensemble system was removed over the wire and exchanged for an 8F sheath, which was positioned over the wire.
A repeat ascending aortic angiogram was performed, and once the valve was determined appropriately positioned, a Glide catheter was advanced over the wire and the Super stiff wire was removed and exchanged for a Wholey wire. The Glide catheter, Wholey wire, and sheath were then removed from the heart, while the purse-string suture was tied down. Balloon dilation of the left sided pulmonary veins was then performed. Direct measurement revealed a 10-mm gradient across the Melody valve and a 20-mm gradient between the ventricular cavity and the femoral arteries, which was deemed acceptable (Fig. 2) . The total fluoroscopy time for this procedure was 13.4 minutes. Temporary sternal closure was performed followed by delayed closure on postoperative day 2.
Postoperative course required a fundoplication, gastrostomy tube, and a tracheostomy because of continued ventilator dependence and gastroesophageal reflux. Four months after surgery, echocardiography demonstrated mild tricuspid valve regurgitation, moderate right ventricle hypertrophy, mild ventricular dysfunction, and a Melody valve with mild stenosis and insufficiency with thin, mobile leaflets. At 5 months (2.5-years-old) after surgery, he experienced a cardiac arrest and was not deemed to be an extracorporeal membrane oxygenation candidate and passed away. Autopsy revealed a severely hypertrophied ventricle and a compressed Melody valve stent secondary to chest compressions (Fig. 3) .
DISCUSSION
The Boston Children's group published their data on surgical implantation on the Melody valve between 2010 and 2014. Forty-eight patients underwent valve implantation at a median age of 10 months in the aortic, mitral, pulmonary, and tricuspid positions. The valve was competent with low gradient in the immediate postoperative phase in all patients. Eight patients experienced central or paravalvular leak, and seven required reoperations for valve-related adverse outcomes. The Kaplan-Meier estimated freedom from mortality or transplantation was 83% at 12 months and 77% at 24 months. 1 Any form of cardiac surgery, including aortic valve surgery, in a patient with single-ventricle physiology is a very high-risk procedure. 5 Valve replacement by a bioprosthesis remains a short-term or midterm palliation that is associated with a high procedural risk when re-replacement becomes necessary in this patient population. 6 Prosthetic valve degeneration is more accelerated in younger patients. 7 When transplantation is not an option, further palliative operations carry very significant and sometimes prohibitive operative risk. Hence, we considered valve-in-valve replacement using a Melody valve, as an off-label use of this device. These valves have shown to have good hemodynamic performance in highpressure environments, in both the systemic and pulmonary circulations. 1, 4 The presence of a dysfunctional bioprosthetic valve provided a good landing zone. We demonstrated that a per-ventricular approach in a single-ventricle patient can be performed successfully. There is some concern that a per-ventricular approach may further worsen a deteriorating ventricle. 8 However, we did not observe any worsening of ventricular function in the postprocedure phase. Patient selection remains paramount when considering using the Melody valve in an off-label manner. The Boston Children's group demonstrated that mortality in their study was predominantly related to patient selection. Hospital mortality was encountered in those with a severely depressed ventricle being supported by mechanical circulation preoperatively. The patients with late mortality exhibited various combinations of ventricular noncompliance, arrhythmias, systolic dysfunction, and pulmonary hypertension before valve replacement that persisted even after replacement. In addition, one patient experienced central regurgitation as a result of implantation into a circulation without significant forward flow (Glenn circulation and patent atrial septal defect). 1 The valve requires sufficient flow across it to create forces that fully open and close the valve. During low flow states, the valve is unable to fully open or close creating central regurgitation.
The decision to perform this operation was on the basis that this would be a "bail-out" procedure. Our rationale was that if we could get a functioning valve into this patient and buy him some time to grow, gain weight, and improve his functional status that we could come back and replace his valve at a later date. We chose to perform a sternotomy over a thoracotomy only approach due to the fact that this child possessed a 5-mm aortopulmonary shunt. A shunt of this size has significant runoff on extracorporeal membrane oxygenation often requiring banding or clipping. Our patient died 5 months after valve implantation. Overall, this patient was a very high-risk candidate for Melody valve implantation.
CONCLUSIONS
Off-label use of the Melody valve continues to demonstrate good short-term results, despite use in the systemic circulation. Operations in patients with single-ventricle physiology pose additional risks, and use of the Melody valve in this population may be an alternative to standard operative surgery especially when transplantation is not an option. This approach provides surgeons with an additional option for palliation.
